Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
出版年份 2023 全文链接
标题
Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
作者
关键词
-
出版物
LEUKEMIA
Volume 37, Issue 6, Pages 1175-1185
出版商
Springer Science and Business Media LLC
发表日期
2023-05-04
DOI
10.1038/s41375-023-01920-1
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium
- (2023) Doris K. Hansen et al. JOURNAL OF CLINICAL ONCOLOGY
- Stability of hybrid versus vaccine immunity against BA.5 infection over 8 months
- (2023) João Malato et al. LANCET INFECTIOUS DISEASES
- Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine
- (2023) Jing Zou et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune responses to COVID‐19 booster vaccinations in intensively anti‐CD38 antibody treated patients with ultra‐high‐risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial
- (2023) Sian E. Faustini et al. BRITISH JOURNAL OF HAEMATOLOGY
- Convalescent Plasma Therapy for COVID-19: A Systematic Review and Meta-Analysis on Randomized Controlled Trials
- (2023) Charalampos Filippatos et al. Viruses-Basel
- P55 MULTIPLE MYELOMA AND SARS-COV-2 INFECTION: AN EUROPEAN HEMATOLOGY ASSOCIATION SURVEY (EPICOVIDEHA) OF 1,221 PATIENTS THROUGH THE DIFFERENT PHASES OF COVID-19 PANDEMIC
- (2023) P. Musto et al. HemaSphere
- Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
- (2022) Laura Vangeel et al. ANTIVIRAL RESEARCH
- Booster BNT162b2 Optimizes SARS-CoV-2 Humoral Response in Myeloma Patients; the Negative Effect of anti-BCMA therapy
- (2022) Evangelos Terpos et al. BLOOD
- COVID-19 breakthrough infections, hospitalizations and mortality in fully vaccinated patients with hematologic malignancies: A clarion call for maintaining mitigation and ramping-up research
- (2022) Lindsey Wang et al. BLOOD REVIEWS
- Depletion of CD38 ‐positive regulatory T cells by anti‐CD38 monoclonal antibodies induces a durable response to SARS‐CoV ‐2 vaccination in patients with plasma cell dyscrasia
- (2022) Toshiki Terao et al. BRITISH JOURNAL OF HAEMATOLOGY
- Immune response to COVID ‐19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T‐cell response
- (2022) Karthik Ramasamy et al. BRITISH JOURNAL OF HAEMATOLOGY
- Third dose of COVID‐19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titers
- (2022) O. Šušol et al. BRITISH JOURNAL OF HAEMATOLOGY
- Shorter Interval between Treatment and COVID Immunization Is Associated With Poor Seroconversion in Patients with Hematological Malignancies
- (2022) Meera Mohan et al. Clinical Lymphoma Myeloma & Leukemia
- Serological response following anti-SARS-CoV-2 vaccination in hematopoietic stem cell transplantation patients depends upon time from transplant, type of transplant and “booster” dose
- (2022) Immacolata Attolico et al. HAEMATOLOGICA
- Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma
- (2022) Toshiki Terao et al. INTERNATIONAL JOURNAL OF HEMATOLOGY
- Convalescent plasma improves overall survival in patients with B-cell lymphoid malignancy and COVID-19: a longitudinal cohort and propensity score analysis
- (2022) Thomas Hueso et al. LEUKEMIA
- Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies
- (2022) Daniel Re et al. Nature Communications
- Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group
- (2022) Noopur S Raje et al. Lancet Haematology
- Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19
- (2022) Csilla Várnai et al. JAMA Network Open
- Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients
- (2022) Sabine Haggenburg et al. Blood Advances
- COVID-19: impact of vaccination in myeloma patients
- (2022) E. Hoornaert et al. ANNALS OF HEMATOLOGY
- Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients
- (2022) Adolfo Aleman et al. CANCER CELL
- Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma
- (2022) Julius C. Enssle et al. CANCER CELL
- COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis
- (2022) Yusuke Ito et al. Clinical Lymphoma Myeloma & Leukemia
- Management of infectious risk of daratumumab therapy in multiple myeloma: A consensus-based position paper from an ad hoc Italian expert panel
- (2022) Corrado Girmenia et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma
- (2022) Ajay K. Nooka et al. JOURNAL OF CLINICAL ONCOLOGY
- Risk of SARS-CoV-2 Breakthrough Infection in Vaccinated Cancer Patients: A Retrospective Cohort Study
- (2022) Anthony Rooney et al. Journal of Hematology & Oncology
- SARS-CoV-2-mRNA Booster Vaccination Reverses Non-Responsiveness and Early Antibody Waning in Immunocompromised Patients – A Phase Four Study Comparing Immune Responses in Patients With Solid Cancers, Multiple Myeloma and Inflammatory Bowel Disease
- (2022) Angelika Wagner et al. Frontiers in Immunology
- Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern
- (2022) Maggie Li et al. Blood Advances
- Outcome of infection with omicron SARS‐CoV ‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report
- (2022) Ola Blennow et al. AMERICAN JOURNAL OF HEMATOLOGY
- Pre-exposure prophylaxis with tixagevimab and cilgavimab (Evusheld©) for COVID-19 among 1112 severely immunocompromised patients
- (2022) Yann Nguyen et al. CLINICAL MICROBIOLOGY AND INFECTION
- Neutralizing antibody responses against SARS‐CoV ‐2 in patients with plasma cell disorders who are on active treatment after two doses of mRNA vaccination
- (2022) Al‐Ola Abdallah et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Response to SARS‐CoV‐2 vaccination and antibodies persistence in multiple myeloma patients
- (2022) Loredana Pettine et al. HEMATOLOGICAL ONCOLOGY
- Secondary infections worsen the outcome of COVID‐19 in patients with hematological malignancies: A report from the ITA‐HEMA‐COV
- (2022) Patrizia Zappasodi et al. HEMATOLOGICAL ONCOLOGY
- Clinical course of Coronavirus Disease-19 in patients with haematological malignancies is characterized by a longer time to respiratory deterioration compared to non-haematological ones: results from a case–control study
- (2022) A. Oliva et al. INFECTION
- Response to anti‐SARS‐CoV ‐2 mRNA vaccines in multiple myeloma and chronic lymphocytic leukemia patients
- (2022) Joanna Zaleska et al. INTERNATIONAL JOURNAL OF CANCER
- High seroconversion rates amongst black and Hispanics with hematologic malignancies after SARS-CoV-2 vaccination
- (2022) Lauren C. Shapiro et al. LEUKEMIA & LYMPHOMA
- Efficacy of Antibodies and Antiviral Drugs against Omicron BA.2.12.1, BA.4, and BA.5 Subvariants
- (2022) Emi Takashita et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody Response to SARS-CoV-2 Vaccination in Patients With Lymphoproliferative Disorders and Plasma Cell Dyscrasias: Anti-Lymphoma Therapy as a Predictive Biomarker of Response to Vaccination
- (2022) Carol Gung et al. Frontiers in Oncology
- Efficacy of SARS-CoV-2 vaccination in patients with monoclonal gammopathies: A cross sectional study
- (2022) Eugenia Abella et al. Life Science Alliance
- Risk factors for severe infection and mortality In patients with COVID ‐19 in patients with multiple myeloma and AL amyloidosis
- (2022) Matthew Ho et al. AMERICAN JOURNAL OF HEMATOLOGY
- Antibody and T‐cell responses by ultra‐deep T‐cell receptor immunosequencing after COVID ‐19 vaccination in patients with plasma cell dyscrasias
- (2022) Alfred Chung et al. BRITISH JOURNAL OF HAEMATOLOGY
- P-161: Oral antivirals ritonavir-nirmatrelvir and molnupiravir are highly effective in patients with multiple myeloma and COVID-19; a singlecenter, prospective study
- (2022) Vassiliki Spiliopoulou et al. Clinical Lymphoma Myeloma & Leukemia
- Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study
- (2022) Carlos K H Wong et al. LANCET
- Immune response to SARS-CoV-2 mRNA vaccination and booster dose in patients with multiple myeloma and monoclonal gammopathies: impact of Omicron variant on the humoral response
- (2022) Paola Storti et al. OncoImmunology
- Antibody Response in Immunocompromised Patients With Hematologic Cancers Who Received a 3-Dose mRNA-1273 Vaccination Schedule for COVID-19
- (2022) Sabine Haggenburg et al. JAMA Oncology
- Early prediction of COVID-19 outcome using artificial intelligence techniques and only five laboratory indices
- (2022) Panagiotis G. Asteris et al. CLINICAL IMMUNOLOGY
- WITHDRAWN: Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
- (2022) Xia Wang et al. JOURNAL OF INFECTION
- Factors associated with infection events after chimeric antigen receptor T-cell therapy for relapsed or refractory multiple myeloma
- (2022) Dian Zhou et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Early Access to Oral Antivirals in High-Risk Outpatients: Good Weapons to Fight COVID-19
- (2022) Giuseppe Bruno et al. Viruses-Basel
- Antibodies and bispecifics for multiple myeloma: effective effector therapy
- (2022) Christopher Cipkar et al. Hematology-American Society of Hematology Education Program
- Cellular therapy for multiple myeloma: what's now and what's next
- (2022) Paula Rodriguez-Otero et al. Hematology-American Society of Hematology Education Program
- Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer
- (2022) Lennard Y. W. Lee et al. JAMA Oncology
- Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom’s Macroglobulinemia after BNT162b2 Booster Vaccination
- (2022) Margherita Rosati et al. Cancers
- Effectiveness of COVID-19 Vaccines against SARS-CoV-2 Omicron Variant (B.1.1.529): A Systematic Review with Meta-Analysis and Meta-Regression
- (2022) Nando Reza Pratama et al. Vaccines
- mRNA-Based Vaccines and Therapeutics for COVID-19 and Future Pandemics
- (2022) Vivek P. Chavda et al. Vaccines
- Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
- (2022) Grace Lai-Hung Wong et al. JAMA Network Open
- Immunogenicity of SARS-CoV-2 vaccines in patients with multiple myeloma: a systematic review and meta-analysis
- (2022) Nipat Chuleerarux et al. Blood Advances
- The potential link between Covid‐19 and multiple myeloma: A new saga
- (2022) Hayder M. Al‐Kuraishy et al. Immunity Inflammation and Disease
- Improved Clinical Outcome of COVID-19 in Hematologic Malignancy Patients Receiving a Fourth Dose of Anti-SARS-CoV-2 Vaccine: An EPICOVIDEHA Report
- (2022) Jon Salmanton-García et al. HemaSphere
- Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
- (2022) Andrea Keppler-Hafkemeyer et al. Nature Cancer
- Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study
- (2021) Akshay Sharma et al. Lancet Haematology
- Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias
- (2021) Andrew R. Branagan et al. Blood Advances
- Low Neutralizing Antibody Responses Against SARS-CoV-2 in Elderly Myeloma Patients After the First BNT162b2 Vaccine Dose
- (2021) Evangelos Terpos et al. BLOOD
- Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution
- (2021) Fulvia Pimpinelli et al. Journal of Hematology & Oncology
- Epidemiology and organ specific sequelae of post-acute COVID19: A Narrative Review
- (2021) Eleni Korompoki et al. JOURNAL OF INFECTION
- Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection
- (2021) David S. Khoury et al. NATURE MEDICINE
- Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma
- (2021) Sarah Bird et al. Lancet Haematology
- Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
- (2021) Ian McDonald et al. npj Vaccines
- Antibody response to COVID ‐19 mRNA vaccine ( Comirnaty ) in myeloma patients treated with high‐dose melphalan and/or immunotherapy
- (2021) Sandra Lockmer et al. AMERICAN JOURNAL OF HEMATOLOGY
- Covid‐19 vaccination in patients with multiple myeloma: Focus on immune response
- (2021) Heinz Ludwig et al. AMERICAN JOURNAL OF HEMATOLOGY
- BNT162b2 COVID ‐19 vaccine is significantly less effective in patients with hematologic malignancies
- (2021) Katrin Herzog Tzarfati et al. AMERICAN JOURNAL OF HEMATOLOGY
- Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR-T cell therapy
- (2021) Binod Dhakal et al. BLOOD
- The 12‐week kinetics of anti‐SARS‐CoV‐2 antibodies in different haematological cancers after vaccination with BNT162b2
- (2021) Francesco Marchesi et al. BRITISH JOURNAL OF HAEMATOLOGY
- Myeloma patients with COVID‐19 have superior antibody responses compared to patients fully vaccinated with the BNT162b2 vaccine
- (2021) Maria Gavriatopoulou et al. BRITISH JOURNAL OF HAEMATOLOGY
- Serological SARS‐CoV‐2 antibody response, potential predictive markers and safety of BNT162b2 mRNA COVID‐19 vaccine in haematological and oncological patients
- (2021) Magdalena Benda et al. BRITISH JOURNAL OF HAEMATOLOGY
- Development of antibody response to SARS‐CoV‐2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy
- (2021) Wei Yee Chan et al. BRITISH JOURNAL OF HAEMATOLOGY
- COVID symptoms, testing, shielding impact on patient‐reported outcomes and early vaccine responses in individuals with multiple myeloma
- (2021) Karthik Ramasamy et al. BRITISH JOURNAL OF HAEMATOLOGY
- Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma
- (2021) Irit Avivi et al. BRITISH JOURNAL OF HAEMATOLOGY
- COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies
- (2021) Francesco Passamonti et al. BRITISH JOURNAL OF HAEMATOLOGY
- Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma
- (2021) Oliver Van Oekelen et al. CANCER CELL
- Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer
- (2021) Sidse Ehmsen et al. CANCER CELL
- Response to mRNA vaccination for COVID-19 among patients with multiple myeloma
- (2021) Samuel D. Stampfer et al. LEUKEMIA
- Low rate of seroconversion after mRNA anti-SARS-CoV-2 vaccination in patients with hematological malignancies
- (2021) Daniel Re et al. LEUKEMIA & LYMPHOMA
- The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment
- (2021) Evangelos Terpos et al. Blood Cancer Journal
- Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study
- (2021) Kazimieras Maneikis et al. Lancet Haematology
- Post-Vaccination Anti-SARS-CoV-2-Antibody Response in Patients with Multiple Myeloma Correlates with Low CD19+ B-Lymphocyte Count and Anti-CD38 Treatment
- (2021) Susanne Ghandili et al. Cancers
- Immunological Response Against SARS-COV-2 After BNT162b2 Vaccine Administration Is Impaired in Allogeneic but Not in Autologous Stem Cell Transplant Recipients
- (2021) Martina Chiarucci et al. Frontiers in Oncology
- Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era
- (2021) Mounzer E Agha et al. Open Forum Infectious Diseases
- Late‐onset hematological complications post COVID ‐19: An emerging medical problem for the hematologist
- (2021) Eleni Korompoki et al. AMERICAN JOURNAL OF HEMATOLOGY
- Distinct neutralization profile of spike variants by antibodies induced upon SARS‐CoV ‐2 infection or vaccination
- (2021) Margherita Rosati et al. AMERICAN JOURNAL OF HEMATOLOGY
- Attenuated humoral immune response following anti‐SARS‐CoV ‐2 vaccine in heavily pretreated patients with multiple myeloma and AL amyloidosis
- (2021) Neta Schiller Salton et al. AMERICAN JOURNAL OF HEMATOLOGY
- Anti-CD38 therapy impairs SARS-CoV-2 vaccine response against alpha and delta variants in patients with multiple myeloma
- (2021) Soledad Henriquez et al. BLOOD
- Effectiveness of the BNT162b2mRNA Covid-19 Vaccine in Patients with Hematological Neoplasms
- (2021) Moshe Mittelman et al. BLOOD
- Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma
- (2021) Julius C. Enßle et al. BLOOD
- Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma
- (2021) Ross S. Greenberg et al. BMC CANCER
- Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation
- (2021) Marco Salvini et al. BONE MARROW TRANSPLANTATION
- Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV‐19 COVID‐19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors
- (2021) Wei Yee Chan et al. BRITISH JOURNAL OF HAEMATOLOGY
- T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies
- (2021) Vincenzo Marasco et al. BRITISH JOURNAL OF HAEMATOLOGY
- Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma
- (2021) Adolfo Aleman et al. CANCER CELL
- Attenuated response to SARS-CoV-2 vaccine in patients with asymptomatic precursor stages of multiple myeloma and Waldenstrom macroglobulinemia
- (2021) Yoshinobu Konishi et al. CANCER CELL
- COVID-19 Vaccine Responses in Patients With Plasma Cell Dyscrasias After Complete Vaccination
- (2021) Mansi R. Shah et al. Clinical Lymphoma Myeloma & Leukemia
- Antibody response after vaccination against SARS-CoV-2 in adults with haematological malignancies: a systematic review and meta-analysis
- (2021) Nico Gagelmann et al. HAEMATOLOGICA
- COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
- (2021) Livio Pagano et al. Journal of Hematology & Oncology
- Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls
- (2021) Samuel Bitoun et al. Journal of Hematology & Oncology
- Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients
- (2021) Robert L. Gottlieb et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of COVID-19 in patients with multiple myeloma based on a global data network
- (2021) J. Martinez-Lopez et al. Blood Cancer Journal
- SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma
- (2021) Nicola Sgherza et al. Blood Cancer Journal
- COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
- (2021) Heinz Ludwig et al. Lancet Haematology
- Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination
- (2021) Evangelos Terpos et al. JAMA Oncology
- Lymphocytopenia and Anti-CD38 Directed Treatment Impact the Serological SARS-CoV-2 Response after Prime Boost Vaccination in Patients with Multiple Myeloma
- (2021) Susanne Ghandili et al. Journal of Clinical Medicine
- Risks of SARS-CoV-2 Breakthrough Infection and Hospitalization in Fully Vaccinated Patients With Multiple Myeloma
- (2021) Lindsey Wang et al. JAMA Network Open
- Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis
- (2021) Deborah Cromer et al. Lancet Microbe
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- Clinical Characteristics of Coronavirus Disease 2019 in China
- (2020) Wei-jie Guan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with Multiple Myeloma receiving systemic anti‐cancer therapy.
- (2020) Gordon Cook et al. BRITISH JOURNAL OF HAEMATOLOGY
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
- (2020) Nicole M Kuderer et al. LANCET
- Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
- (2020) Evangelos Terpos et al. LEUKEMIA
- Remdesivir for the Treatment of Covid-19 — Preliminary Report
- (2020) John H. Beigel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patients with cancer appear more vulnerable to SARS-COV-2: a multi-center study during the COVID-19 outbreak
- (2020) Mengyuan Dai et al. Cancer Discovery
- Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany
- (2020) Monika Engelhardt et al. HAEMATOLOGICA
- A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward
- (2020) Bo Wang et al. Journal of Hematology & Oncology
- Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
- (2020) Francesco Passamonti et al. Lancet Haematology
- COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study
- (2020) Lennard Y W Lee et al. LANCET ONCOLOGY
- Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network
- (2020) Heinz Ludwig et al. LEUKEMIA
- Covid-19 in patients with hematological and solid cancers at a Comprehensive Cancer Center in Germany
- (2020) Khalid Shoumariyeh et al. Cancer Medicine
- Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients
- (2020) Abi Vijenthira et al. BLOOD
- Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
- (2020) Ajai Chari et al. BLOOD
- Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma
- (2019) Hareth Nahi et al. PLoS One
- Immunomodulatory drugs and the risk of serious infection in multiple myeloma: systematic review and meta-analysis of randomized and observational studies
- (2018) Min Chen et al. ANNALS OF HEMATOLOGY
- Risk factors for infections in newly diagnosed Multiple Myeloma patients: A Danish retrospective nationwide cohort study
- (2018) Rasmus Sørrig et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients
- (2014) C. Blimark et al. HAEMATOLOGICA
- The Proteasome Inhibitor Bortezomib Enhances the Susceptibility to Viral Infection
- (2009) M. Basler et al. JOURNAL OF IMMUNOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started